| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJI.1830181122 |
| P698 | PubMed publication ID | 2462501 |
| P2093 | author name string | Turner M | |
| Matsuda T | |||
| Hirano T | |||
| Sato K | |||
| Shimizu M | |||
| Tang B | |||
| Miyasaka N | |||
| Feldmann M | |||
| Maini R | |||
| Buchan G | |||
| P2860 | cites work | Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin | Q24299103 |
| Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells | Q24322083 | ||
| Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion of beta 2 interferon by human fibroblasts | Q27485094 | ||
| B cell growth and differentiation activity of interleukin-HP1 and related murine plasmacytoma growth factors. Synergy with interleukin 1. | Q30757082 | ||
| Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter | Q34161873 | ||
| Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II. | Q34162731 | ||
| B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells | Q34359809 | ||
| Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors | Q34378498 | ||
| Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production | Q34586194 | ||
| Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis | Q35209798 | ||
| Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities | Q35597069 | ||
| Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor | Q36352519 | ||
| B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes | Q36354573 | ||
| cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. | Q36421041 | ||
| Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved | Q36463524 | ||
| Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts | Q36479212 | ||
| A cytokine network in human diploid fibroblasts: interactions of beta-interferons, tumor necrosis factor, platelet-derived growth factor, and interleukin-1 | Q36833475 | ||
| Expression of cell-cycle-dependent genes in phytohemagglutinin-stimulated human lymphocytes | Q37528225 | ||
| Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). | Q37546825 | ||
| Novel B-cell maturation factor from spontaneously autoimmune viable motheaten mice | Q37577691 | ||
| B-cell-tropic interleukins in murine systemic lupus erythematosus (SLE) 1. | Q39370113 | ||
| Rheumatoid factor: its nature, specificity, and production in rheumatoid arthritis | Q39403361 | ||
| Autoimmunity--a perspective | Q40204553 | ||
| B cell differentiation factor in synovial fluid of patients with rheumatoid arthritis | Q40212574 | ||
| The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells | Q41867235 | ||
| Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons | Q45848193 | ||
| Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis | Q46376254 | ||
| Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. | Q52832954 | ||
| Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. | Q54779287 | ||
| Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor | Q57584941 | ||
| Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas | Q59077136 | ||
| Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells | Q68181266 | ||
| Absence of antiviral activity in recombinant B cell stimulatory factor 2 (BSF-2) | Q69821975 | ||
| Serum levels of interleukin-6 and acute phase responses | Q69907015 | ||
| IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures | Q93590941 | ||
| P433 | issue | 11 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1797-1801 | |
| P577 | publication date | 1988-11-01 | |
| P1433 | published in | European Journal of Immunology | Q5412727 |
| P1476 | title | Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis | |
| P478 | volume | 18 |
| Q35833439 | 4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. |
| Q90266648 | A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity |
| Q40663585 | A child who was feverish for 2 years |
| Q39877191 | A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression |
| Q35927412 | A four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases |
| Q24310416 | A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family |
| Q36371158 | A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis |
| Q28360066 | A prospective study of renal disease in patients with early rheumatoid arthritis |
| Q28769936 | A reappraisal of the evidence that rheumatoid arthritis and several other idiopathic diseases are slow bacterial infections. |
| Q71446665 | A sigma ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice |
| Q24679426 | APC-derived cytokines and T cell polarization in autoimmune inflammation |
| Q28646310 | Activation of interleukin-6 gene expression through the NF-kappa B transcription factor |
| Q42799388 | Activation of neutrophil reactive-oxidant production by synovial fluid from patients with inflammatory joint disease. Soluble and insoluble immunoglobulin aggregates activate different pathways in primed and unprimed cells |
| Q41234204 | Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis |
| Q58826994 | Agalactosyl IgG in pristane-induced arthritis. Pregnancy affects the incidence and severity of arthritis and the glycosylation status of IgG |
| Q35555049 | Agalactosyl glycoforms of IgG autoantibodies are pathogenic |
| Q67841838 | Alteration in progression of murine autoimmune disease by treatment with a novel immunomodulator, SM-8849 |
| Q45868500 | Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery |
| Q53805508 | An interleukin-6 transgene expressed in B lymphocyte lineage cells overcomes the T cell-dependent establishment of normal levels of switched immunoglobulin isotypes. |
| Q41733014 | Analysis of immunoglobulins secreted by hybridomas derived from rheumatoid synovia |
| Q41658738 | Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies |
| Q33998632 | Anti-CagA immunoglobulin G responses correlate with interleukin-8 induction in human gastric mucosal biopsy culture |
| Q36394198 | Anti-Inflammatory Activity of a Polymeric Proanthocyanidin from Serjania schiedeana. |
| Q40963908 | Anti-cytokine therapy in rheumatoid arthritis |
| Q41609736 | Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo |
| Q36628145 | Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models |
| Q34071253 | Anti-interleukin 6 receptor antibody treatment in rheumatic disease |
| Q38132000 | Aryl hydrocarbon receptor and experimental autoimmune arthritis |
| Q51127034 | Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators. |
| Q36228672 | Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells |
| Q34135558 | Averting inflammation by targeting the cytokine environment |
| Q92987312 | B cell checkpoints in autoimmune rheumatic diseases |
| Q33345109 | B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system? |
| Q24316254 | BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth |
| Q40467512 | Beneficial effects of tumour necrosis factor-alpha (TNF-α) blockade in rheumatoid arthritis (RA) |
| Q37087438 | Biologic treatments for systemic rheumatic diseases |
| Q34001621 | Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention |
| Q46538950 | Characterisation of monoclonal antibodies to ovine interleukin-6 and the development of a sensitive capture ELISA. |
| Q34700673 | Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis |
| Q78467480 | Characterization of anti-mouse interleukin-6 receptor antibody |
| Q36579912 | Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys |
| Q36824499 | Chlorogenic acid induces apoptosis to inhibit inflammatory proliferation of IL-6-induced fibroblast-like synoviocytes through modulating the activation of JAK/STAT and NF-κB signaling pathways |
| Q33566549 | Circadian rhythm of serum interleukin-6 in rheumatoid arthritis |
| Q41320668 | Clinical response to non-surgical periodontal treatment in patients with interleukin-6 and interleukin-10 polymorphisms |
| Q36243965 | Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan |
| Q41733125 | Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene |
| Q34556797 | Constitutive production of interleukin-6 and immunologic features in cardiac myxomas |
| Q42049241 | Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. |
| Q68358721 | Contrasting effects of interferon-gamma and interleukin-4 on the interleukin-6 activity of stimulated human monocytes |
| Q72920727 | Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration |
| Q74557826 | Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements |
| Q33802181 | Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. |
| Q36996859 | Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review |
| Q45258734 | Cytokine and nitric oxide production in the acute phase of bacterial cell wall-induced arthritis |
| Q35249619 | Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis |
| Q37433285 | Cytokines and autoimmune disease |
| Q72344490 | Cytokines and autoimmunity |
| Q72665342 | Cytokines in the peritoneal fluid of patients with endometriosis |
| Q74476919 | Cytokines serum levels as the markers of thyroid activation in Graves' disease |
| Q78124718 | Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice |
| Q72269085 | Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma |
| Q33578241 | Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis |
| Q44487409 | Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures |
| Q37600383 | Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. |
| Q38998373 | Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis |
| Q33765050 | Differential normalization of mucosal interleukin-8 and interleukin-6 activity after Helicobacter pylori eradication. |
| Q35834390 | Differential regulation of intracellular factors mediating cell cycle, DNA repair and inflammation following exposure to silver nanoparticles in human cells |
| Q73374754 | Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis |
| Q36817687 | Diversification of the IgG molecule by oligosaccharides |
| Q39881401 | Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis |
| Q34259037 | Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. |
| Q81356317 | Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model |
| Q71549301 | Effect of IL-10 on collagen-induced arthritis in mice |
| Q42093264 | Effect of anticancer drugs on the release of interleukin-6 in vitro |
| Q33771907 | Effect of tryptase inhibition on joint inflammation: a pharmacological and lentivirus-mediated gene transfer study |
| Q74095902 | Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis |
| Q43204148 | Effects of triazolodiazepine on the production of interleukin-6 from murine spleen cells and rabbit synovial cells in vitro |
| Q41650994 | Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis |
| Q37608027 | Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. |
| Q73222786 | Elevated interleukin-6 in schizophrenia |
| Q46024897 | Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology |
| Q67557643 | Elevated serum interleukin-6 levels in patients with acute hepatitis |
| Q72188625 | Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent |
| Q40726545 | Endometriosis: the host response |
| Q41751738 | Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression |
| Q34238473 | Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice |
| Q69119779 | Establishment of strongly neutralizing monoclonal antibody to human interleukin-6 and its epitope analysis |
| Q71877370 | Evaluation of interleukin-6 in rheumatoid arthritis as an activity criterion |
| Q33687315 | Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps |
| Q37316594 | Evidence that cytokines play a role in rheumatoid arthritis |
| Q72611596 | Expression of endogenous retroviruses, ERV3 and lambda 4-1, in synovial tissues from patients with rheumatoid arthritis |
| Q68007091 | Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha |
| Q70493642 | Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice |
| Q24682989 | Functional murine interleukin 6 receptor with the intracisternal A particle gene product at its cytoplasmic domain. Its possible role in plasmacytomagenesis |
| Q38765969 | Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro. |
| Q41658732 | Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies |
| Q34148654 | IL-6 in autoimmune disease and chronic inflammatory proliferative disease |
| Q34248105 | IL-6 in inflammation, immunity, and disease |
| Q41627715 | IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2 |
| Q39079705 | IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro |
| Q47901598 | IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice |
| Q34288655 | IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation |
| Q91691068 | IL-6: a cytokine at the crossroads of autoimmunity |
| Q36243951 | IL-6: from laboratory to bedside |
| Q71919762 | IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV |
| Q68004797 | Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha |
| Q33685988 | Identifying the association between interleukin-6 and lichen planus: A meta-analysis |
| Q34308376 | IgG1 plasmacytosis in interleukin 6 transgenic mice |
| Q42942352 | Immunoregulatory role of interleukin 10 in rheumatoid arthritis |
| Q45124159 | In situ hybridization of IL-6 in rheumatoid arthritis |
| Q44501533 | Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration |
| Q34398929 | Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1β production in macrophages by targeting STAT3. |
| Q72314545 | Induction of autoimmune disease by graft-versus-host reaction across MHC class II difference: modification of the lesions in IL-6 transgenic mice |
| Q44780199 | Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response |
| Q28083759 | Inflammation induced loss of skeletal muscle |
| Q34154676 | Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells. |
| Q93089887 | Inflammatory patterns of antrochoanal polyps in the pediatric age group |
| Q58181592 | Influence of IL-6 on Proliferation and Differentiation of Tonsillar Lymphocytes and Detection of IL-6 Producing Cells in Tonsil |
| Q67887905 | Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells |
| Q77849071 | Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells |
| Q77144365 | Inhibitory effects of anti-rheumatic drugs containing magnosalin, a compound from 'Shin-i' (Flos magnoliae), on the proliferation of synovial cells in rheumatoid arthritis models |
| Q67914182 | Interactions between interleukin-1 and basic fibroblast growth factor on articular chondrocytes. Effects on cell growth, prostanoid production, and receptor modulation |
| Q39637547 | Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor κB ligand |
| Q38553533 | Interferon regulatory factor 5 in human autoimmunity and murine models of autoimmune disease. |
| Q40105940 | Interleukin (IL-6) Immunotherapy |
| Q37553940 | Interleukin 6 and rheumatoid arthritis |
| Q34734696 | Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir |
| Q68551212 | Interleukin 6 is a differentiation factor for human megakaryocytes in vitro |
| Q34228814 | Interleukin 6 promotes murine lupus in NZB/NZW F1 mice |
| Q42216323 | Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis |
| Q44975468 | Interleukin-1 beta induces synthesis and secretion of interleukin-6 in human chondrocytes |
| Q38232568 | Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth |
| Q36731954 | Interleukin-6 and its relation to inflammation and disease |
| Q36559880 | Interleukin-6 and the acute phase response |
| Q40336917 | Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells |
| Q41636231 | Interleukin-6 can prime THP-1 macrophages for enhanced production of tumor necrosis factor-α in response to LPS |
| Q40771131 | Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense |
| Q40850225 | Interleukin-6 in biology and medicine |
| Q37189514 | Interleukin-6 in clinical medicine |
| Q72891553 | Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis |
| Q72813392 | Interleukin-6 inhibits bone formation in vitro |
| Q36778655 | Interleukin-6 is linked to longitudinal rates of cortical thinning in aging |
| Q83889010 | Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane |
| Q41702676 | Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis |
| Q67901970 | Interleukin-6 production by human gingival fibroblasts |
| Q35611724 | Interleukin-6 production in posttransplant lymphoproliferative disease |
| Q37792471 | Interleukin-6: From identification of the cytokine to development of targeted treatments |
| Q36561156 | Interleukin-6: discovery of a pleiotropic cytokine |
| Q36280356 | Interleukin-6: structure-function relationships. |
| Q36988763 | Involvement of interleukin-1 (IL-1), IL-6, IL-2, and IL-4 in generation of cytolytic T cells from thymocytes stimulated by a Mycoplasma fermentans-derived product |
| Q42017481 | Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. |
| Q24316553 | JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression |
| Q54582048 | LPS hypersensitivity of gp130 mutant mice is independent of elevated haemopoietic TLR4 signaling. |
| Q72045494 | Lipopolysaccharide-Mediated Induction of the Bovine Interleukin-6 Gene in Monocytes Requires Both NF-κB and C/EBP Binding Sites |
| Q37111624 | Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease |
| Q37832677 | Lung transplantation: infection, inflammation, and the microbiome |
| Q57462089 | Macrophage depletion decreases IgG anti-DNA in cultures from (NZB · NZW)F1 spleen cells by eliminating the main source of IL-6 |
| Q35838787 | Management of early inflammatory arthritis. Intervention with immunomodulatory agents: new pharmacological developments |
| Q28268945 | Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis |
| Q73526256 | Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis |
| Q43850656 | Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib. |
| Q37073348 | Molecular basis of new approaches to the therapy of rheumatoid arthritis |
| Q24318531 | Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth |
| Q40433213 | Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease |
| Q42048606 | Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. |
| Q36980940 | Mycoplasma fermentans-derived high-molecular-weight material induces interleukin-6 release in cultures of murine macrophages and human monocytes |
| Q33543136 | Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway |
| Q41233076 | Neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis: priming and activation in vivo |
| Q35766373 | Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides |
| Q40642412 | Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages |
| Q74425550 | Osteoporosis in rheumatoid arthritis |
| Q33578088 | Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells |
| Q33576859 | Phospholipase D1 mediates TNFalpha-induced inflammation in a murine model of TNFalpha-induced peritonitis |
| Q33410688 | Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice |
| Q44418441 | Polymorphism at position -174 of IL-6 gene is associated with susceptibility to chronic periodontitis in a Caucasian Brazilian population |
| Q41534378 | Preparation of monoclonal antibodies against the IL-6 signal transducer, gp130, that can inhibit IL-6-mediated functions |
| Q35782480 | Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes |
| Q73085686 | Pristane-induced arthritis is CD4+ T-cell dependent |
| Q41289167 | Production and modulation of interleukin 6 synthesis by synoviocytes derived from patients with arthritic disease |
| Q54674737 | Proviral integration site 2 is required for interleukin-6 expression induced by interleukin-1, tumour necrosis factor-α and lipopolysaccharide. |
| Q58479948 | Quantification of cross-reactive idiotype-positive rheumatoid factor produced in autoimmune rheumatic diseases. An indicator of clonality and B cell proliferative mechanisms |
| Q37695128 | RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. |
| Q92924037 | Recent Advances in Electrochemical and Optical Biosensors Designed for Detection of Interleukin 6 |
| Q72463299 | Reduced galactosyltransferase mRNA levels are associated with the agalactosyl IgG found in arthritis-prone MRL-lpr/lpr strain mice |
| Q24816793 | Regulatory T cells in rheumatoid arthritis |
| Q47572222 | Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients |
| Q26998608 | Revisiting the 1986 molecular cloning of interleukin 6 |
| Q54300423 | Rheumatoid arthritis bone fragility is associated with upregulation of IL17 and DKK1 gene expression. |
| Q35541858 | Role of Monocytes in Atherogenesis |
| Q72065803 | Role of cytokines in experimental arthritis |
| Q40663408 | Role of cytokines in the pathogenesis of monoclonal gammopathies |
| Q40346195 | Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation |
| Q77627732 | Role of pro-inflammatory cytokines in rheumatoid arthritis |
| Q34764999 | Salivary markers of inflammation in response to acute stress |
| Q67524937 | Second Jenner international glycoimmunology meeting |
| Q43831234 | Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes |
| Q41546325 | Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis |
| Q38755912 | Selected cytokine pathways in rheumatoid arthritis |
| Q73426148 | Selective cyclooxygenase-2 (COX-2) inhibitors reduce anti-Mycobacterium antibodies in adjuvant arthritic rats |
| Q39765865 | Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis |
| Q72427040 | Selective presence of IgG2b inducing factor in synovial fluid of patients with rheumatoid arthritis |
| Q44705234 | Sequential measurement of the murine acute-phase protein serum amyloid P component (SAP) as an indicator of graft-versus-host disease following allogeneic bone marrow transplantation in mice |
| Q34581815 | Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias |
| Q40336418 | Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis |
| Q70123615 | Significance of interleukin-6 in patients with inflammatory bowel disease |
| Q55417294 | Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. |
| Q34092469 | Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy |
| Q38335680 | Site-specific mutagenesis of human interleukin-6 and its biological activity |
| Q24563585 | Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6 |
| Q41922954 | Some plasma component is essential for IL-6 secretion by Neutrophils |
| Q37813491 | Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis |
| Q47925973 | Stimulatory effect of interleukin-6 on plasminogen activator activity from human dental pulp cells |
| Q36019061 | Studies on early events of Borrelia burgdorferi-induced cytokine production in immunodeficient SCID mice by using a tissue chamber model for acute inflammation |
| Q35954629 | Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab |
| Q64377813 | Sustained interleukin‐6 signalling leads to the development of lymphoid organ‐like structures in the lung |
| Q33566039 | Synovial tissue macrophages and joint erosion in rheumatoid arthritis |
| Q40541780 | T-cell antigen receptors in rheumatoid arthritis |
| Q26782493 | Targeting interleukin-6 for noninfectious uveitis |
| Q37224863 | The -174G/C and -572G/C interleukin 6 promoter gene polymorphisms in mexican patients with rheumatoid arthritis: a case-control study |
| Q89099512 | The Relationship Between Serum Pentraxine 3 Levels and Hematological Markers in Patients With Rheumatoid Arthritis |
| Q35170906 | The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response |
| Q72068462 | The effect of interleukin‐1 on cytokine gene expression in cultured human articular chondrocytes analyzed by messenger rna phenotyping |
| Q34792254 | The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. |
| Q34731226 | The paradigm of IL-6: from basic science to medicine |
| Q27690908 | The pathological and physiological roles of IL-6 amplifier activation |
| Q69112410 | The role of cytokines in the pathogenesis of rheumatoid arthritis |
| Q39738345 | The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis |
| Q28214190 | The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases |
| Q40581267 | The value of C-reactive protein measurement in rheumatoid arthritis |
| Q36368339 | The varying faces of IL-6: From cardiac protection to cardiac failure. |
| Q77627754 | Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody |
| Q35724900 | Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions |
| Q38110210 | Tocilizumab in pediatric rheumatology: the clinical experience |
| Q37682799 | Tocilizumab in the treatment of rheumatoid arthritis and beyond |
| Q84308432 | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production |
| Q42452643 | Transcriptional roles of CCAAT/enhancer binding protein-beta, nuclear factor-kappaB, and C-promoter binding factor 1 in interleukin (IL)-1beta-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes |
| Q36736731 | Transforming Growth Factor-β1 and Laminin-111 Cooperate in the Regulation of Expression of Interleukin-6 and Interleukin-8 in Synovial Fibroblasts |
| Q24564656 | Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis |
| Q43760473 | Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human sy |
| Q36920666 | Vascular endothelium, cytokines, and the pathogenesis of inflammatory synovitis |
| Q84600861 | [Interleukin 6 in the physiopathology of rheumatoid arthritis] |
| Q42049265 | p38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements |
Search more.